BioImpacts : BI
Alpha 7 nicotinic acetylcholine receptor, COVID-19, Cholinergic anti-inflammatory pathway, Vagus nerve stimulation
The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Mehranfard, Danial and Speth, Robert C., "Cholinergic anti-inflammatory pathway and COVID-19" (2022). HPD Articles. 41.
© 2022 The Author(s).